Status:
COMPLETED
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
Lead Sponsor:
Pfizer
Conditions:
Growth Hormone Deficiency
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and b...
Eligibility Criteria
Inclusion
- Glucocorticosteroid treatment for 12 months at least
- Bone age \< 15 years for a boy and \< 13 years for a girl
- Child measured height \< - 2 SD, Child currently treated by GH
Exclusion
- Known diabetes (type 1 or type 2)
- A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00163189
Start Date
January 1 2005
End Date
December 1 2014
Last Update
February 21 2024
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Nord
Amiens, France, 80030
2
Centre Hospitalier Intercommunal d'Annemasse-Bonneville, Service de Pédiatrie et Néonatologie
Annemasse, France, 74107
3
Hôpital Saint Jacques
Besançon, France, 25030
4
Groupe hospitalier Est- Hôpital Femme, Mère, Enfant
Bron, France, 69677